Lycopene and soy isoflavones in the treatment of prostate cancer.
Dietary intake of lycopene and soy has been associated with a lower risk of prostate cancer. In vitro studies with lycopene and genistein, a soy isoflavone, have shown induction of apoptosis and inhibition of cell growth in androgen-sensitive (LNCaP) and androgen-independent (PC3 and VeCaP) prostate cancer cell lines. In a previous Phase II clinical trial in prostate cancer patients, we observed prostate-specific antigen (PSA) stabilization with soy isoflavone intake. In this Phase II clinical trial, we investigated the efficacy of lycopene alone or in combination with soy isoflavones on serum PSA levels in men with prostate cancer. To be eligible for the study, men with prostate cancer had to have rising serum PSA following local therapy or while on hormone therapy. Study population included 71 eligible patients who had 3 successive rising PSA levels or a minimum PSA of 10 ng/ml at 2 successive evaluations prior to starting therapy. Subjects were randomly assigned to receive a tomato extract capsule containing 15 mg of lycopene alone (n = 38) or together with a capsule containing 40 mg of a soy isoflavone mixture (n = 33) twice daily orally for a maximum of 6 mo. One patient on the lycopene arm did not receive therapy due to his inability to ingest the study pill. There was no decline in serum PSA in either group qualifying for a partial or complete response. However, 35 of 37 (95%) evaluable patients in the lycopene group and 22 of 33 (67%) evaluable patients in the lycopene plus soy isoflavone group achieved stable disease described as stabilization in serum PSA level. The data suggest that lycopene and soy isoflavones have activity in prostate cancer patients with PSA relapse disease and may delay progression of both hormone-refractory and hormone-sensitive prostate cancer. However, there may not be an additive effect between the 2 compounds when taken together. Future studies are warranted to further investigate the efficacy of lycopene and soy isoflavones in prostate cancer as well as the mechanism of potential negative interaction between them.
Vaishampayan
Ulka
U
Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Hussain
Maha
M
Banerjee
Mousumi
M
Seren
Soley
S
Sarkar
Fazlul H
FH
Fontana
Joseph
J
Forman
Jeffrey D
JD
Cher
Michael L
ML
Powell
Isaac
I
Pontes
J Edson
JE
Kucuk
Omer
O
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D002338:Carotenoids / Q000009:adverse effects / Q000627:therapeutic use*; D019587:Dietary Supplements; D018450:Disease Progression; D004359:Drug Therapy, Combination; D019833:Genistein / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007529:Isoflavones; D000077276:Lycopene; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013025:Glycine max; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007529:Isoflavones; D002338:Carotenoids; D019833:Genistein; D017430:Prostate-Specific Antigen; D000077276:Lycopene